Compass Therapeutics (CMPX) Competitors $1.89 +0.07 (+3.85%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPX vs. WVE, ELVN, XFOR, ZYME, PHVS, SYRE, MLYS, NTLA, NRIX, and GYREShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Wave Life Sciences (WVE), Enliven Therapeutics (ELVN), X4 Pharmaceuticals (XFOR), Zymeworks (ZYME), Pharvaris (PHVS), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Intellia Therapeutics (NTLA), Nurix Therapeutics (NRIX), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Compass Therapeutics vs. Wave Life Sciences Enliven Therapeutics X4 Pharmaceuticals Zymeworks Pharvaris Spyre Therapeutics Mineralys Therapeutics Intellia Therapeutics Nurix Therapeutics Gyre Therapeutics Compass Therapeutics (NASDAQ:CMPX) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings. Does the MarketBeat Community favor CMPX or WVE? Wave Life Sciences received 321 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 81.03% of users gave Compass Therapeutics an outperform vote while only 67.90% of users gave Wave Life Sciences an outperform vote. CompanyUnderperformOutperformCompass TherapeuticsOutperform Votes4781.03% Underperform Votes1118.97%Wave Life SciencesOutperform Votes36867.90% Underperform Votes17432.10% Does the media favor CMPX or WVE? In the previous week, Wave Life Sciences had 7 more articles in the media than Compass Therapeutics. MarketBeat recorded 18 mentions for Wave Life Sciences and 11 mentions for Compass Therapeutics. Wave Life Sciences' average media sentiment score of 0.88 beat Compass Therapeutics' score of 0.44 indicating that Wave Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Wave Life Sciences 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CMPX or WVE? Compass Therapeutics presently has a consensus price target of $13.38, suggesting a potential upside of 607.67%. Wave Life Sciences has a consensus price target of $21.17, suggesting a potential upside of 154.81%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Wave Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is CMPX or WVE more profitable? Compass Therapeutics has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Compass Therapeutics' return on equity of -32.37% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -32.37% -30.67% Wave Life Sciences -66.50%-280.57%-52.90% Which has better earnings & valuation, CMPX or WVE? Compass Therapeutics has higher earnings, but lower revenue than Wave Life Sciences. Wave Life Sciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass Therapeutics$850K307.48-$42.49M-$0.37-5.11Wave Life Sciences$108.30M11.77-$57.51M-$0.79-10.52 Do institutionals & insiders have more ownership in CMPX or WVE? 68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are owned by institutional investors. 28.5% of Compass Therapeutics shares are owned by company insiders. Comparatively, 29.1% of Wave Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, CMPX or WVE? Compass Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.93, indicating that its stock price is 193% less volatile than the S&P 500. SummaryCompass Therapeutics beats Wave Life Sciences on 11 of the 18 factors compared between the two stocks. Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$261.36M$2.97B$5.55B$8.05BDividend YieldN/A1.87%5.09%4.22%P/E Ratio-5.1130.5322.7318.81Price / Sales307.48500.45406.97107.57Price / CashN/A168.6838.1834.62Price / Book1.623.226.814.34Net Income-$42.49M-$72.35M$3.22B$247.85M7 Day Performance-2.58%4.14%2.40%2.83%1 Month Performance11.83%7.74%3.77%3.46%1 Year Performance14.55%-22.32%16.96%5.87% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics3.4028 of 5 stars$1.89+3.8%$13.38+607.7%+15.9%$261.36M$850,000.00-5.1120Short Interest ↑Analyst RevisionWVEWave Life Sciences4.2263 of 5 stars$6.83+1.5%$22.18+224.8%+40.0%$1.05B$108.30M-6.15240Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageELVNEnliven Therapeutics2.3031 of 5 stars$18.91+3.8%$40.33+113.3%+9.7%$926.67MN/A-9.9550News CoveragePositive NewsXFORX4 Pharmaceuticals3.973 of 5 stars$5.34-6.4%$85.00+1,493.3%-88.7%$926.49M$2.56M-59.2780Earnings ReportAnalyst ForecastStock SplitNews CoverageGap UpHigh Trading VolumeZYMEZymeworks2.7588 of 5 stars$12.88+2.5%$21.00+63.0%+47.0%$896.15M$76.30M-8.59460Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsPHVSPharvaris2.0349 of 5 stars$17.06+1.3%$42.67+150.1%-27.4%$892.07MN/A-6.0930Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeSYRESpyre Therapeutics1.9423 of 5 stars$14.67+3.8%$49.57+237.9%-56.7%$884.25M$890,000.00-1.96100Upcoming EarningsNews CoveragePositive NewsMLYSMineralys Therapeutics2.4156 of 5 stars$13.56+1.6%$33.00+143.4%+16.9%$879.72MN/A-3.7328Upcoming EarningsShort Interest ↑News CoverageNTLAIntellia Therapeutics4.6615 of 5 stars$8.48+2.0%$36.68+332.6%-61.6%$877.82M$57.88M-1.56600Upcoming EarningsPositive NewsGap UpNRIXNurix Therapeutics1.9722 of 5 stars$11.47-0.8%$30.44+165.4%-14.7%$874.43M$56.42M-3.97300Analyst ForecastNews CoverageGYREGyre Therapeutics0.0669 of 5 stars$9.32+2.8%N/A-32.6%$873.69M$105.76M186.4040Upcoming EarningsNews Coverage Related Companies and Tools Related Companies WVE Alternatives ELVN Alternatives XFOR Alternatives ZYME Alternatives PHVS Alternatives SYRE Alternatives MLYS Alternatives NTLA Alternatives NRIX Alternatives GYRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMPX Stock Free CMPX Stock Alerts